Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples

Seung Gyu Yun, Sang wook Kim, Ji Yeon Sohn, Yunjung Cho

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)


    Background: The seroprevalence rate of human T-lymphotropic virus I and II (HTLV-I/II) in Korean blood donors has been known as 0.004%, and HTLV-I/II Ab screening test has been performed since 2008 in Korea. Korea Ministry of Food and Drug Safety (MFDS) approved two chemiluminescent microparticle immunoassays (CMIA) for testing HTLV-I/II antibody, ABBOTT PRISM HTLV-I/HTLV-II and ARCHITECT rHTLV-I/II. A multicenter performance evaluation study in Europe and Japan was carried out with the new electrochemiluminescence immunoassay (ECLIA) for HTLV-I/II antibody detection, Elecsys HTLV-I/II assay which launched in 2017, but not in Korea. We aimed to evaluate the clinical performance of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II for the detection of HTLV-I/II antibody with Korean samples. Methods: For sensitivity evaluation, 100 HTLV-I/II-positive Korean standards from Korean Red Cross and two HTLV-II-positive samples that were purchased from Seracure were used. For the specificity, 500 potential donor specimens from Korea University Hospital healthcare center were used. All the samples were simultaneously analyzed by the two HTLV-I/II assays, Elecsys HTLV-I/II assay and ARCHITECT rHTLV-I/II assay. Results: Elecsys HTLV-I/II assay and ARCHITECT rHTLV-I/II assay showed a complete agrement. Elecsys HTLV-I/II assay showed 100% sensitivity (95% CI: 96.38-100.0) and specificity (95% CI: 99.26-100.0). Conclusions: Elecsys HTLV-I/II assay is as reliable as ARCHITECT rTHLV-I/II assay, and can be used as a screening test for HTLV-I/II in Korea.

    Original languageEnglish
    Article numbere22909
    JournalJournal of Clinical Laboratory Analysis
    Issue number6
    Publication statusPublished - 2019 Jul

    Bibliographical note

    Funding Information:
    Roche Korea supported this study through financial, instrumentation, and reagent contribution. The funding organization played no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the report for publication. The authors would like to acknowledge the technical support provided by Hyuk-Jun Kim who performed the tests at Korea University Hospital.

    Publisher Copyright:
    © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.


    • HTLV-I/II
    • Korean
    • blood donor screening
    • clinical performance

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Hematology
    • Public Health, Environmental and Occupational Health
    • Clinical Biochemistry
    • Medical Laboratory Technology
    • Biochemistry, medical
    • Microbiology (medical)


    Dive into the research topics of 'Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples'. Together they form a unique fingerprint.

    Cite this